Home Page - ChinaBio® Today

In the News

The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs

>>Burrill podcast...

Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...

Site Search

>> Advanced Search

Free Newsletter

>> Preview...

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

SFDA What's New

Subscriber Content

News & Analysis

Featured Companies

Industry Insights

Deals & Financings

Trials & Approvals

Stem Cells

CRO/CMO Services

Gov't & Regulatory

Legal & IP Issues

Stock Watch

Week in Review

Archived Articles

Featured Event...

BioBay Investor Forum 2010

November 3-4, 2010 | Suzhou, China

Early bird registration now open – only $150!

The Third Annual BioBay Investor Forum in Suzhou, presented by ChinaBio^®, is a two-day event bringing together investors and early stage life science companies throughout China, the fastest growing life science park in China. Up to 20 companies will be presenting their technologies to over 200 attendees, including more than 50 VCs and investors. This will be the ninth Investor Forum ChinaBio^® LLC has organized in China. These events have raised over $350M for early stage companies in China.

Apply to present for free!

>> See http://www.BBIF2010.com for more information.

ChinaBio® Today - Focused solely on China biotech...

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotechnology companies and industry events, as well as global issues affecting the China life science market.

Email subscriptions are free. Just click here to register for free daily summaries of key events in China biotech. Paid subscriptions provide full access to all articles and analysis, including the over 2000 articles we've published on the biotech industry over the last four years. There is also an option to contact our analysts to answer your questions. Click here to learn more about our subscription plans.

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

Wise Sky “Disappointed” by Emergent BioSolutions (in: News & Analysis) Sep 2, 2010: Wise Sky (Hong Kong) Limited formally said it was “disappointed” by the decision of Emergent BioSolutions to forego marketing its anthrax vaccine, BioThrax®, in China. In June 2009, the two companies signed an exclusive marketing agreement for China, enlisting Wise Sky to seek government contracts and conduct other product promotions for the vaccine. More details....

Stock Symbol: (NYSE: EBS)

Golden Helix Finds China Distributor for its SNP Software (in: News & Analysis) Sep 1, 2010: Golden Helix of the US has signed up CloudScientific, a China life sciences software company, to distribute its analytic services and proprietary software in China. The software, the SNP & Variation Suite (SVS), offers several modules to facilitate SNP, copy number, and genome-wide association analyses. More details....

Will Roche Job Cuts Include China Positions? (in: News & Analysis) Aug 31, 2010: Roche Holding AG is planning to make “massive” job cuts soon, according to newspaper reports, involving “more than several hundreds” of employees around the world including positions in sales, R&D, production and administration. The reduction in employee counts comes at the same time Roche is expanding in China. More details....

Stock Symbol: (VX: ROG)

BGI Deepens Relationship with Denmark (in: News & Analysis) Aug 31, 2010: BGI, known as the Beijing Genomics Center until 2008, has signed a formal collaboration agreement with the University of Copenhagen. The two entities will study the genetic causes of diseases such as type 2 diabetes, obesity, and cancer. The new agreement gives official standing to a cooperative relationship that has existed for several years. More details....

Fosun Completes Half of $30 Million Investment in Chindex (in: Deals & Financings) Aug 30, 2010: Chindex International said Fosun Pharmaceutical has purchased 933,022 of its shares at $15 per share. The investment is part of a previously announced transaction that will establish a medical device JV between the two companies. Chindex is spinning off its medical device manufacturing and distribution business into the JV, which will be owned 51% by Fosun. More details....

Stock Symbols: (NSDQ: CHDX) (SHEX: 600196)

The Week in Review: Golden Meditech Raises $40 Million (in: Week in Review) Aug 28, 2010: Golden Meditech raised $40 million in private equity for its autologous blood recovery medical device JV; Boehringer Ingelheim held the formal opening of an R&D center in Shanghai; 3SBio in-licensed the China rights to an anti-rejection drug from Isotechnika; China PharmaHub will distribute radioactive glass spheres in China to treat liver cancer; Xiamen Innovax Biotech’s vaccine for hepatitis B was effective in a Phase III trial; Lotus Pharma began a Phase I trial of R-Bambuterol®, an asthma treatment; and Aoxing Pharma received SFDA approval to begin a clinical trial of a treatment for opioid addiction. More details….

Stock Symbols: (HKEX: 801) (NSDQ: SSRX) (TSX: ISA) (OTCBB: WRLC) (OTCBB: LTUS) (NYSE Amex: AXN)

China PharmaHub to Distribute Liver Cancer Treatment (in: Deals & Financings) Aug 27, 2010: China PharmaHub Corp. signed an exclusive agreement allowing the company to distribute radioactive glass spheres to treat liver cancer. The agreement covers China and several other countries in Southeast Asia. PharmaHub said the technology is similar to one approved by the FDA in the US, presumably TheraSphere. More details....

Stock Symbol: (OTCBB: WRLC)

Boehringer Ingelheim Opens Center of Competence in Shanghai (in: News & Analysis) Aug 26, 2010: Boehringer Ingelheim held the formal opening of its Center of Competence (CoC) in Shanghai, a $12.7 million facility dedicated to optimizing APIs and chemical intermediates sourced from China. The CoC is one part of BI’s $127 million expansion project in China, announced last year. The company is also expanding its manufacturing plant in Shanghai Zhangjiang High-Tech Park. More details...

Lotus Pharma Starts China Clinical Trial of Asthma Drug (in: Trials & Approvals) Aug 26, 2010: Lotus Pharmaceuticals has begun a Phase I trial of R-Bambuterol®, an asthma treatment. The company said preclinical studies of R-Bambuterol showed efficacy but lower toxicity than Bambuterol, which can cause liver and cardiovascular side effects. Bambuterol is already commercially available in China. More details....

Stock Symbol: (OTCBB: LTUS)

Aoxing Receives Approval for Trial of Drug Dependence Therapy (in: Trials & Approvals) Aug 25, 2010: Aoxing Pharmaceutical has been given SFDA approval to begin a clinical trial of buprenorphine/naloxone sublingual tablets as a maintenance therapy for opioid addiction. Aoxing plans to start the trial of the therapy, which is not yet available in China, later this year. The test will be completed in mid-2011 and, if all goes well, it will launch in mid-2012. More details....

Stock Symbol: (NYSE Amex: AXN)